John Rincón-Hekking

John Rincón-Hekking

Auto-generated profile, based on publicly available information

John Rincón-Hekking

Nference, inc., One Main Street, Suite 400, East Arcade, Cambridge, MA 02142, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
CPColin Pawlowski
Colin Pawlowski
JRJohn Rincón-Hekking
John Rincón-Hekking
SASamir Awasthi
Samir Awasthi
VPViral Pandey
Viral Pandey
PLPatrick Lenehan
Patrick Lenehan
VSVenky Soundararajan
Venky Soundararajan
To assess the association of COVID-19 vaccines and non-COVID-19 vaccines with cerebral venous sinus thrombosis (CVST). We retrospectively analyzed a cohort of 771,805 vaccination events across 266,094 patients in the Mayo Clinic Health System between 01/01/2017 and 03/15/2021. The primary outcome was a positive diagnosis of CVST, identified either by the presence of a corresponding ICD code or by an NLP algorithm which detected positive diagnosis of CVST within free-text clinical notes. For each vaccine we calculated the relative risk by dividing the incidence of CVST in the 30 days following vaccination to that in the 30 days preceding vaccination. We identified vaccination events for all FDA-approved COVID-19 vaccines including Pfizer-BioNTech (n = 94,818 doses), Moderna (n = 36,350 doses) and Johnson & Johnson - J&J (n = 1,745 doses). We also identified vaccinations events for 10 common FDA-approved non-COVID-19 vaccines (n = 771,805 doses). There was no statistically significant difference in the incidence rate of CVST in 30-days before and after vaccination for any vaccine in this population. We further found the baseline CVST incidence in the study population between 2017 and 2021 to be 45 to 98 per million patient years. This real-world evidence-based study finds that CVST is rare and is not significantly associated with COVID-19 vaccination in our patient cohort. Limitations include the rarity of CVST in our dataset, a relatively small number of J&J COVID-19 vaccination events, and the use of a population drawn from recipients of a SARS-CoV-2 PCR test in a single health system.

23 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
CPColin Pawlowski
Colin Pawlowski
JRJohn Rincón-Hekking
John Rincón-Hekking
SASamir Awasthi
Samir Awasthi
VPViral Pandey
Viral Pandey
PLPatrick Lenehan
Patrick Lenehan
VSVenky Soundararajan
Venky Soundararajan
Cerebral venous sinus thrombosis (CVST) has been reported in a small number of individuals who have received the mRNA vaccines 1 or the adenoviral vector vaccines for COVID-19 in the US 2 and Europe 3 . Continued pharmacovigilance is integral to mitigating the risk of rare adverse events that clinical trials are underpowered to detect, however, these anecdotal reports have led to the pause or withdrawal of some vaccines in many jurisdictions and exacerbated vaccine hesitancy at a critical moment in the fight against the COVID-19 pandemic. We investigated the frequencies of CVST seen among individuals who received FDA-authorized COVID-19 vaccines from Pfizer-BioNTech (n = 94,818 doses), Moderna (n = 36,350 doses) and Johnson & Johnson - J&J (n = 1,745 doses), and among individuals receiving one of 10 FDA-approved non-COVID-19 vaccines (n = 771,805 doses). Comparing the incidence rates of CVST in 30-day time windows before and after vaccination, we found no statistically significant differences for the COVID-19 vaccines or any other vaccines studied in this population. In total, we observed 3 cases of CVST within the 30 days following Pfizer-BioNTech vaccination (2 females, 1 male; Ages (years): [79, 80, 84]), including one individual with a prior history of thrombosis and another individual with recent trauma in the past 30 days. We did not observe any cases of CVST among the patients receiving Moderna or J&J vaccines in this study population. We further found the baseline CVST incidence in the study population between 2017 and 2021 to be 45 to 98 per million patient years. Overall, this real-world evidence-based study highlights that CVST is rare and is not significantly associated with COVID-19 vaccination. In addition, there is a need for a concerted international effort to monitor EHR data across diverse patient populations and to investigate the underlying biological mechanisms leading to these rare clotting events.

1 September 2022
Verified
Journal Article
Open access
ZLZach Landis-Lewis
Zach Landis-Lewis
CSCooper Stansbury
Cooper Stansbury
JRJohn Rincón
John Rincón
CGColin Gross
Colin Gross
Feedback loops are vital for decision-making and behavior change in health systems, but not all feedback is of equal value. Clinical performance feedback to healthcare professionals and teams has potential for large effects on clinical practice, but evidence suggests that low-value performance feedback is widespread. A primary barrier to understanding the value of feedback loops in health systems may be a lack of a well-defined model and shared semantics for the information that they carry. An ontology for audit and feedback research may be used to address these issues by standardizing feedback intervention metadata. Research describing feedback interventions recognizes differences between the content of the feedback and its delivery process. However, terms describing feedback intervention content are inconsistent, and appear to vary considerably between audit and feedback frameworks, which can result in confusion around what is being delivered in a performance summary. Our objective was to develop an ontology of a performance summary in a clinical performance feedback intervention for the purposes of standardizing metadata. We developed the Performance Summary Display Ontology (PSDO) iteratively by 1) identifying terms for classes from behavior change theories relating to feedback interventions and cognitive theories of visualization, 2) searching for relevant existing ontologies and classes, and 3) using the terms to specify information content and visual displays in published examples of dashboard displays and feedback reports. PSDO is a lightweight application ontology that specifies performance information content and its representations for the purpose of feedback intervention research and evaluation. PSDO contains 3 primary domains: 1) Performance information content, based on constructs from behavior change theories, 2) Marks and their qualities, based on constructs from visualization theories, and 3) roles that link marks, information content, and other emergent characteristics, as interpreted information. PSDO may enable standardization of metadata for the study of feedback interventions.